ReviewBMC cancer2020
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
Review in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 5 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025).Frontiers in immunology · 2026Pooled it
- Prognostic significance of circulating tumor DNA in urothelial carcinoma patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.Frontiers in immunology · 2025Pooled it
- Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study.Journal of cardiothoracic surgery · 2024Pooled it
- Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.Nature communications · 2025Trial
- Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study.BMC cancer · 2025Trial
- PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.Journal for immunotherapy of cancer · 2023Trial
- Pan-immune-inflammation value as a prognostic and predictive biomarker in metastatic non-small cell lung cancer treated with nivolumab: A real-world study.Oncology letters · 2026Article
- Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study.The oncologist · 2026Observational
- Characteristics and hematological indicators predictors of immunotherapy response in advanced non-small cell lung cancer.BMC cancer · 2026Article
- Article
- Exploration of immunotherapy modalities in stage III unresectable non-small cell lung cancer (Review).Oncology letters · 2026Review
- The value of DNA repair gene and TP53 co-mutation in predicting the response of non-small cell lung cancer to immunotherapy.Discover oncology · 2026Article
- Predictive value of nutritional biomarkers for immune checkpoint inhibitor efficacy in patients with non-small cell lung cancer.Frontiers in nutrition · 2026Article
- Inferring tumor immune microenvironment -related risk states from pretreatment H&E pathomics and clinical biomarkers to predict checkpoint inhibitor pneumonitis in advanced NSCLC: a multicenter multimodal study.Frontiers in immunology · 2026Article
- Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3).ImmunoTargets and therapy · 2026Article
- First-Line Treatment of Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor: A Case Report and Review of the Literature.Case reports in oncological medicine · 2026Article
- Progression-Free Survival Under Immune Checkpoint Inhibitors for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.Oncology and therapy · 2025Article
- Association of Erythrocyte-Related Indices with Immune-Related Adverse Events and Survival of Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2025Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICI) either alone or in combination with chemotherapy have expanded our choice of agents for the palliative treatment of non-small cell lung cancer (NSCLC) patients. Unfortunately, not all patients will experience favorable response to treatment with ICI and may even suffer from severe side effects. Therefore, prognostic and predictive markers, beyond programmed death ligand 1 (PD-L1) expression status, are of utmost importance for decision making in the palliative treatment. This review focuses on clinical, laboratory and genetic markers, most of them easily to obtain in the daily clinical practice.
resultsRecently, a number of prognostic and predictive factors in association to palliative ICI therapy have been described in NSCLC. Besides biometric parameters and clinical characteristics of the tumor, there are useful markers from routine blood sampling as well as innovative soluble genetic markers which can be determined before and during ICI treatment. Additionally, the level of evidence is noted.
conclusionsThese factors can be helpful to predict patients' outcome and tumor response to ICI. They should be implemented prospectively in ICI based clinical trials to develop reliable algorithms for palliative NSCLC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.